Earendil Labs closed a $787 million financing to accelerate an AI‑powered biologics pipeline spanning autoimmune diseases and oncology. Lead investors include Dimension and Luminous Ventures; Sanofi participated and already holds partnership agreements with the company. Earendil said its platform has produced more than 40 programs and listed roughly 19 pipeline candidates publicly, with at least one program ready for Phase 2. The capital will fund multiple IND‑enabling efforts and expand R&D infrastructure across the U.S. and China. The raise signals sustained investor appetite for AI‑first drug discovery and positions Earendil to consider an IPO in Hong Kong while deepening industry collaborations.